Figure 4: Clinical response of LEC/chTNT-3 and toceranib phosphate. A) Pie charts illustrating clinical benefit (defined as being characterized by stable disease and partial response) by day 10 and day 28 of the study. B) Kaplan-Meier curve showing progression-free survival based on dosing cohorts. p=0.08 as determined by a log-rank test. C) Kaplan-Meier curve showing effect of dosing cohorts on survival. p=0.2 as determined by a log-rank test.